Although there are few studies of the effects of glucagon infusion in patients with obesity and/or MASLD, there is some evidence that the expected effect of glucagon on amino acid catabolism may be attenuated. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.